Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rituximab Maintenance Therapy Versus Observation in Aggressive CD20+ Lymphoma and Mantle Cell Lymphoma - a Prospective Randomized Phase III Trial

NCT01933711 is registered in ClinicalTrials.gov with University Hospital Heidelberg as lead sponsor.

NCT NCT01933711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01933711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rituximab Maintenance Therapy Versus Observation in Aggressive CD20+ Lymphoma and Mantle Cell Lymphoma - a Prospective Randomized Phase III Trial
Lead sponsor
University Hospital Heidelberg
Phase
Phase 3
Overall status
Unknown status
Start date
July 31, 2002
Completion date
December 31, 2018
Enrollment
328 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cd20+ aggressive lymphoma, mantle cell lymphoma